Clinical Trial

Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

Name: Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD — clinical trial record (NCT07694986)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), in combination with trastuzumab or nivolumab to confirm the highest dose of the study treatment that can be given safely to participants with Breast Cancer (BC) with Leptomeningeal Disease (LMD).

Trial Details

NCT Number	NCT07694986
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: United States Department of Defense
Conditions	Breast Cancer, Leptomeningeal Disease
Enrollment	30 participants
Start Date	2026-08
Primary Completion	2029-08 (estimated)
Study Completion	2030-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-10